News Release December 24, 2014 PeptiDream Inc http://www.peptidream.com / （Ticker Code：4587 TSE Mothers） PeptiDream Announces Bristol-Myers Squibb has Initiated Discovery Programs using PeptiDream’s Peptide Discovery Platform System (PDPS) TOKYO, JAPAN – December 24th, 2014 – PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(Tokyo:4587) announced today that BristolMyers Squibb (NYSE:BMY) has initiated discovery programs using PeptiDream’s Peptide Discovery Platform System (PDPS). Building on the Technology License Agreement, signed in September of 2013, and the successful completion of the technology transfer of the PDPS technology from PeptiDream, Bristol-Myers Squibb will initiate discovery programs using the PDPS technology in accordance with the Technology License Agreement. Under the terms of the Technology License Agreement, PeptiDream will receive upfront and annual technology access payments, and will be eligible to receive development milestones and royalties on future sales of products that arise from use of the PDPS technology. PeptiDream will continue to identify macrocylic peptides as potential drug candidates for Bristol-Myers Squibb’s targets under the ongoing discovery alliance between the two companies, which was previously extended until October 2015. Bristol-Myers Squibb will own all rights to lead peptides and will be responsible for all subsequent research and development as pharmaceutical candidates. PeptiDream will continue to receive research funding and is eligible to receive milestone payments upon the successful achievement of certain development milestones and royalties on future sales of products that arise from the collaboration. [Comments from Patrick Reid, CSO and Keiichi Masuya, COO, of PeptiDream Inc] “We greatly look forward to the initiation of discovery programs at Bristol-Myers Squibb using PeptiDream’s PDPS platform and continuing our long standing collaborations of discovering and developing constrained peptide therapeutic candidates toward the clinic.” <About PeptiDream Inc.> PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS) , a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit www.peptidream.com Enquiries: PeptiDream Inc. Patrick C Reid +81-3-5790-9991 (Tokyo) EMAIL: [email protected]